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Hereditary hemorrhagic telangiectasia (HHT), a genetic bleeding disorder leading to systemic arteriovenous malformations
(AVMs), is caused by loss-of-function mutations in the ALK1/ENG/Smad1/5/8 pathway. Evidence suggests that HHT
pathogenesis strongly relies on overactivated PI3K/Akt/mTOR and VEGFR2 pathways in endothelial cells (ECs). In the
BMP9/10-immunoblocked (BMP9/10ib) neonatal mouse model of HHT, we report here that the mTOR inhibitor, sirolimus, and
the receptor tyrosine kinase inhibitor, nintedanib, could synergistically fully block, but also reversed, retinal AVMs to avert
retinal bleeding and anemia. Sirolimus plus nintedanib prevented vascular pathology in the oral mucosa, lungs, and liver of
the BMP9/10ib mice, as well as significantly reduced gastrointestinal bleeding and anemia in inducible ALK1-deficient adult
mice. Mechanistically, in vivo in BMP9/10ib mouse ECs, sirolimus and nintedanib blocked the overactivation of mTOR and
VEGFR2, respectively. Furthermore, we found that sirolimus activated ALK2-mediated Smad1/5/8 signaling in primary ECs
— including in HHT patient blood outgrowth ECs — and partially rescued Smad1/5/8 activity in vivo in BMP9/10ib mouse ECs.
These data demonstrate that the combined correction of endothelial Smad1/5/8, mTOR, and VEGFR2 pathways opposes HHT
pathogenesis. Repurposing of sirolimus plus nintedanib might provide therapeutic benefit in patients with HHT.

Introduction

Hereditary hemorrhagic telangiectasia (HHT), also known as
Rendu-Osler-Weber syndrome, is an autosomal dominant genetic
disease with a prevalence of approximately 1 in 5,000 individuals
(1). HHT is a hemorrhagic vascular dysplasia characterized by the
development of mucocutaneous telangiectasias and arteriovenous
malformations (AVMs) in multiple tissues and organs. Particularly
affected is the vasculature of the liver, lungs, and oronasal and
gastrointestinal (GI) mucosa. In its most severe manifestations,
HHT can lead to highly debilitating and life-threatening events,
such as severe epistaxis and internal bleeding. HHT is also associated with secondary complications, which include anemia, cerebral abscess, and embolism following pulmonary AVMs, as well as
high-output cardiac failure consecutive to liver AVMs (2, 3).
At least 85% of patients with HHT carry disease-causing lossof-function mutations in the genes ENG (encoding endoglin) or
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ACVRL1 (encoding activin receptor–like kinase 1, ALK1), which
define the 2 disease subtypes: HHT1 (OMIM #187300) and HHT2
(OMIM #600376), respectively (4, 5). Mutations have also been
reported in SMAD4 (6) (encoding Smad4) and GDF2 (7) (encoding
bone morphogenetic protein 9, BMP9), which cause rare and atypical forms of the disease called juvenile polyposis/HHT combined
syndrome (OMIM #175050) and HHT-like vascular anomaly syndrome (OMIM #615506), respectively. BMP9, ALK1, endoglin,
and Smad4 are members of the transforming growth factor β signaling superfamily, and all functionally interact in the same signal
transduction axis (8). The cell surface receptor complex composed
of the coreceptor endoglin, the endothelial BMP type I receptor
ALK1, and a BMP type II receptor (e.g., BMPR2) is activated by
sequential binding to the circulating ligands BMP9 and BMP10
(9–11). Mutations in BMPR2 cause familial pulmonary arterial
hypertension (PAH), which can be observed in some patients with
HHT2 (12), further supporting the notion that ALK1 and BMPR2
functionally interact. ALK1-endoglin receptor activation leads
to phosphorylation of the signal transducers Smad1, Smad5, and
Smad8 to trigger the formation of Smad1/5/8-Smad4 complexes
that translocate into the nucleus to control specific gene expression programs (13).
HHT pathogenesis is triggered by a reduction in Smad1/5/8
signaling in ECs. Indeed, HHT-causing mutations decrease
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Smad1/5/8 response to ALK1-endoglin receptor activation by
BMP9 (14–16). Consistent with this model, ALK1, endoglin,
or Smad4 inactivation in mice and zebrafish leads to vascular
defects, which include hypervascularization and AVMs (17–25).
Downstream from ALK1-endoglin receptor loss of function, the
exact pathways involved in HHT pathogenesis and ultimately,
AVM development — i.e., the formation of direct shunts between
an artery and a vein — remain incompletely understood (26).
However, concordant studies have shown that HHT is associated
with abnormal reactivation of angiogenesis (27) and that overactivated proangiogenic pathways, such as VEGF signaling, are
required for the development of the vascular pathology of HHT
models (28, 29). In vitro data in cell cultures have further revealed
that VEGFR2 phosphorylation and activity were increased upon
ALK1 silencing (30), and that endoglin silencing affected VEGFR2 trafficking to increase its downstream signaling (31). Transcriptomic data in ECs have also demonstrated that ALK1 negatively controlled VEGFR2 (KDR gene) expression (32, 33). In vivo,
Vegfr2 knockdown was reported to block hypervascularization
and AVMs in Alk1iΔEC mice (30) and pharmacological inhibition of
VEGFR2 reduced disease severity in EngiΔEC mice (31). Also, recent
clinical trials have indicated that intravenous treatment with the
VEGF-blocking antibody, bevacizumab, provided some therapeutic benefits in patients severely affected by HHT (34, 35). In summary, although the field has not reached a consensus on the exact
mechanism by which ALK1-endoglin loss of function activates
VEGF signaling, there is strong evidence that VEGF/VEGFR2 signaling is a key contributor to the pathogenic process of HHT.
PI3K/Akt overactivation is also involved in AVM development
in ALK1-deficient (30) and endoglin-deficient (31) mice and in
patients with HHT2 (36). Specifically, ribosomal protein S6 (S6)
phosphorylation, a downstream effector of mTORC1 and Akt, was
reported to be increased in the ECs of AVMs in the Alk1iΔEC mouse
retina and in BMP9- and BMP10-immunoblocked (BMP9/10ib)
mice (30), another HHT model. In addition, administration of
PI3K inhibitors, such as wortmannin, partially reduced retinal
AVM numbers in Alk1iΔEC, EngiΔEC, and Smad4iΔEC mice (25, 30, 31).
Akt1 deficiency also mitigated AVM pathology in the Smad4iΔEC
model (25). Thus, overactivated VEGFR2 and PI3K/Akt/mTOR
pathways are critical drivers — in addition to ALK1-endoglin loss
of function — of HHT pathogenesis and AVM development.
Recently, we (32) and others (37) have reported that tacrolimus
(Tac) was associated with Smad1/5/8 signaling activating properties, both in vitro in primary ECs and in vivo in mouse models of
HHT and PAH. Spiekerkoetter et al. further reported in a cell-based
BMP/Smad transactivation assay and in human pulmonary arterial
ECs that the mTOR inhibitor sirolimus (Siro, rapamycin), a macrolide analog of Tac, also activated Smad1/5/8, although less potently
than Tac (37). These data suggest the intriguing possibility that Siro
could both prevent mTOR overactivation and rescue Smad1/5/8
signaling in HHT models. In line with this hypothesis, a 2006
case study reported the potential beneficial effect of an immunosuppressive regimen, which contained Siro, in a probable HHT
patient who underwent liver transplantation after high-output cardiac failure and hepatic AVM development (38). In this patient, the
authors observed a reduction in angiodysplasia and mucosal hemorrhage. They proposed that the combination of Siro plus aspirin, in

the antirejection regimen, could have contributed to the observed
effects in this patient (38).
Several receptor tyrosine kinase (RTK) inhibitors that target VEGFR2 are FDA/EMA approved; one of these, pazopanib,
showed beneficial effects in ALK1-deficient mice (39) and in a
cohort of patients with HHT (40). A recent case study reported
that nintedanib (Nin, BIBF 1120), a VEGFR2-targeting RTK inhibitor that is approved for idiopathic pulmonary fibrosis (IPF) treatment, produced marked reductions in epistaxis and skin telangiectasias in a patient affected by both HHT and IPF (41). Nin is of
particular interest compared with other classical RTK inhibitors
because it has a narrow spectrum of inhibition and is associated
with minimal adverse effects.
In this context and in the current study, we sought to determine whether concurrent pharmacological targeting of Smad1/5/8
reduction, and of mTOR and VEGFR2 activation, could rescue the
signaling defects and vascular pathology of HHT. We report that
Siro and Nin, when administered in combination, mechanistically
synergize at the transcriptional and signaling levels to efficiently
prevent and reverse the vascular pathology, and associated bleeding and anemia, in 2 HHT mouse models.

Results

Siro and Nin combination treatment prevents vein dilation, hypervascularization, and AVM development in the retina of the tBMP9/10ib
mice. Recently, we reported the development of an HHT mouse
model, which uses the transmammary route for administering
BMP9- and BMP10-blocking antibodies to nursing mouse pups (22,
32), hereafter referred to as the transmammary-treated, BMP9/10immunoblocked (tBMP9/10ib) mice. We showed that this model, which has the advantage of being less invasive for the pups and
more suitable for the analysis of large cohorts, leads to reduced
ALK1 signaling and the development of a robust HHT-like pathology in the retinal vasculature of the pups (22, 32). In this model, we
found that Tac significantly activated endothelial ALK1 signaling in
vivo and prevented hypervascularization of the tBMP9/10ib retina.
Further analyses of Tac efficacy in preventing vascular pathology
in tBMP9/10ib mice revealed, however, a relatively modest effect
of the drug on AVM development (32). These data prompted us to
determine whether the macrolide analog of Tac, Siro (administered
alone and in combination with Nin), is more potent in reducing the
vascular pathology of the tBMP9/10ib retina.
Studies were conducted prior to these experiments to determine the appropriate dosing and injection schedule of the drugs in
pups. The highest dose of Siro that did not affect normal vascular
development was chosen (0.5 mg/kg, i.p. injection of the pups,
assessed in the neonatal retina). Similarly, in order to prevent
changes in retinal vascular development, we determined that Nin
should be given every third day and not before P5. With this schedule for Nin injection, the highest dose of the drug that did not affect
physiological vascular development was determined to be 0.3 mg/
kg (i.p., data not shown). Coadministration of Siro and Nin (Siro +
Nin) at these dosing and injection schedules did not significantly
affect normal vascular growth, indicating that physiological angiogenesis in the retina was not inhibited by the drug combination
(Supplemental Figure 1; supplemental material available online
with this article; https://doi.org/10.1172/JCI127425DS1). At this
jci.org   Volume 130   Number 2   February 2020
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Figure 1. Siro + Nin prevents vein dilation, hypervascularization, and AVMs in the tBMP9/10ib mouse retina. (A) Schematic representation of the protocol of disease induction (i.p. injections of the lactating dams with anti-BMP9/10 antibodies, anti-BMP9/10 mAbs) and of drug treatments (i.p. injections
of the pups with Siro and/or Nin). Arrowheads indicate the postnatal days of injection. Control (CTRL) mouse pups were obtained by injecting the lactating
dams with isotype controls and by directly injecting them with DMSO. Pups were euthanized at P6. (B–P) Representative images of retinas stained with
fluorescent isolectin B4 (green) from CTRL (B, G, and L) mice and tBMP9/10ib mice treated with vehicle (DMSO; C, H, and M), Siro (D, I, and N), Nin (E, J,
and O), or the combination of Siro and Nin (F, K, and P). Higher magnification in G–K and L–P shows respectively retinal vein diameter (yellow arrowheads)
and retinal vascular fields (plexus area) between an artery (a) and a vein (v). Arrows denote AVMs. Scale bars: 500 μm (B–F), 200 μm (G–K), and 100 μm
(L–P). (Q–T) Scatter plots measuring AVM number (Q), AVM diameter (R), vein diameter (S), and vascular plexus density (T) in CTRL and tBMP9/10ib mice
treated as in B–F. Data represent individual retinas and mean ± SEM (n = 14, 38, 28, 12, and 20 retinas for the CTRL, DMSO, Siro, Nin, and Siro + Nin groups,
respectively); Kruskal-Wallis test, post hoc Dunn’s multiple-comparisons test. *P < 0.05; **P < 0.01; ****P < 0.0001.

dosing, liquid chromatography/mass spectrometry (LC-MS) analyses measured average serum concentrations of 9.0 nM Siro and
5.3 nM Nin in the injected P6 pups.
As shown in Figure 1A and described previously (22, 32),
vascular pathology in pups was initiated at P3 by 1 i.p. injection of the dams with anti-BMP9/10 antibodies. Mouse pups
944
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were administered preventively and daily with Siro from P3 to
P5 (0.5 mg/kg, i.p.) and with Nin at P5 (0.3 mg/kg, i.p.). Mice
were then analyzed at P6 (Figure 1A), a time point at which retinal vessel dilation, hypervascularization, and AVMs can readily be observed and quantified in this model (22, 32). In the
tBMP9/10ib retinas, Siro significantly reduced AVM number
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(AVM number, mean = 3.79 ± 0.30 in DMSO-treated
tBMP9/10ib retinas vs. mean = 1.57 ± 0.19 in Sirotreated tBMP9/10ib retinas, P ≤ 0.01). Knowing that
evidence is strong to suggest that VEGFR2 signaling is
increased in HHT models and that Siro demonstrated
no efficacy in inhibiting VEGFR2-mediated MAPK signaling activation in primary ECs (Supplemental Figure 2
and ref. 42), we asked whether the VEGFR2 inhibitor Nin
could increase Siro potency in preventing AVMs. Combination treatment with the 2 drugs resulted in a significant
increase in Siro’s anti-AVM effect (Figure 1, B–K and Q;
AVM number after treatment, mean = 0.35 ± 0.11, P ≤
0.0001 vs. DMSO-treated tBMP9/10ib retinas, and P ≤
0.05 vs. Siro-treated tBMP9/10ib retinas). The Siro + Nin
combination did not further increase the effect of Siro on
vein dilation and vascular density, as Siro alone was sufficient to fully correct these 2 defects (Figure 1, L–P, S, and
T). Measurement of the diameter of the few remaining
AVMs identified in the retina of the Siro + Nin–treated
mice also revealed no difference compared with treatment with Siro alone (Figure 1R). Together, these data in
tBMP9/10ib mice show that Siro fully normalized vein
dilation and hypervascularization, and significantly lowered AVM number and size in the retina. Furthermore,
and more strikingly, Nin significantly strengthened the
anti-AVM effect of Siro.
Siro + Nin prevents anemia and retinal bleeding in
tBMP9/10ib mice. We next assessed pathology progression in tBMP9/10ib pups at P9. As before, vascular
pathology in pups was initiated at P3 by 1 i.p. injection
of the dams with anti-BMP9/10 antibodies (Figure
2A). Complete blood count (CBC) revealed significant
reductions in hematocrit level, red blood cell (RBC)
Figure 2. Siro + Nin prevents anemia in tBMP9/10ib mice. (A) Schematic representanumber, and hemoglobin level (Figure 2B), indication of the protocol for disease induction and drug treatments. Pups were euthanized
tive
of anemia in P9 tBMP9/10ib pups. Furthermore,
at P9. (B) Scatter plots measuring hematocrit (HCT) level, red blood cell (RBC) number,
severe cardiomegaly (Figure 2, C and D) and splenoand hemoglobin (Hb) level in P9 control (CTRL) and tBMP9/10ib mice treated with Siro
+ Nin at P3–P8 (as in A) or P6–P8 (see Figure 4A). Data represent individual mice and
megaly (Figure 2C) developed in tBMP9/10ib mice.
mean ± SEM (n = 26–29, 35–40, 18, 11 mice for the CTRL, DMSO, Siro + Nin [P3–P8],
Splenomegaly was accompanied by an expansion of
and Siro + Nin [P6–P8] groups, respectively); HCT and RBC analyses: Kruskal-Wallis
the red pulp (Figure 2D), indicating the presence of
test, post hoc Dunn’s multiple-comparisons test; Hb analysis: 1-way ANOVA, Tukey’s
splenic erythropoietic stress response consecutive to
multiple-comparisons test. CBC parameters of the controls were within the expected
anemia. These data prompted us to investigate whether
ranges for C57BL/6J neonates. (C and D) P9 mouse heart and spleen analyses of CTRL
and tBMP9/10ib mice treated as in A. Heart/body and spleen/body weight ratios are
tBMP9/10ib mice were actively bleeding. Inspection of
shown in C. Data represent individual mice and mean ± SEM (n = 9–11, 12, and 9 mice
the retinas using whole-mount IHC with an antibody
for the CTRL, DMSO, and Siro + Nin groups, respectively); 1-way ANOVA, Tukey’s
directed against the RBC marker Ter119 revealed the
multiple-comparisons test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Heart
presence of strongly immunoreactive patches in muland spleen sections stained with H&E are shown in D. lf, lymphoid follicle; rp, red
tiple areas of the tBMP9/10ib retinas (Figure 3, A, B,
pulp. Scale bars: 1 mm (D, heart), 10 μm (D, spleen).
and M). Single-cell resolution confocal analyses and
3D reconstruction showed the presence of RBC patches
and AVM diameter (Figure 1, B–D, G–I, Q, and R). In addition, as
outside the tBMP9/10ib retinal vasculature (Figure 3, D–F and
we observed previously for Tac at the same dosing (0.5 mg/kg,
G–I, and animation in Supplemental Video 1). Interestingly,
P3–P5, i.p.) (32), Siro prevented vein dilation (Figure 1S) and the
isolectin B4–positive projections could clearly be identified
increase in density of the vascular plexus (Figure 1, B–D, L–N,
near the center of some of these RBC accumulations, suggestand T). In contrast, Nin at the tested dosing failed to reduce any
ing that they might represent transversal vascular projections
of the investigated vascular defects of the tBMP9/10ib retinas
at the origin of the bleeding (Figure 3, G–I, arrows, and Supple(Figure 1, B, C, E, G, H, J, L, M, O, and Q–T).
mental Video 1). Treatment of the tBMP9/10ib mice with Siro
Although Siro treatment was able to significantly reduce
+ Nin from P3 to P8 (Figure 2A) significantly reduced the area
AVM number and size, its preventive effect was only partial
occupied by retinal bleeding (Figure 3, A–M) and fully prevented
jci.org   Volume 130   Number 2   February 2020
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Figure 3. Siro + Nin prevents retinal bleeding in tBMP9/10ib mice. (A–L) Representative images showing microbleeds (dotted orange lines in A–C) in
retinas stained with fluorescent isolectin B4 (green) and anti-Ter119 antibody (red) from control (CTRL; A and D–F) and tBMP9/10ib mice treated with
DMSO (B and G–I) or Siro + Nin (C and J–L), as in Figure 2A. Dotted white lines in B indicate AVMs. Higher magnifications in D–L show the extending deeper
retinal plexus (arrowheads marked as “d” and orthogonal view [xz and yz planes] of the stack of images at the level of the dotted lines are shown in D, G,
and J). Orthogonal views in D, G, and J show superficial vascular plexus (yellow arrowheads marked as “s”), vascular branches projecting to the outer layer
of the retina (white arrows), and microbleeds (asterisks). Focal plane views (E, H, and K) and 3D reconstructions (F, I, and L) identify microbleeds. Scale
bars: 500 μm (A–C) and 50 μm (D–L). (M) Scatter plot measuring bleeding areas, expressed as a percentage of the retinal vascular area occupied by extravascular accumulation of RBCs in mice treated as in Figure 2A. Data represent mean ± SEM (n = 6, 4, 4 mice for the CTRL, DMSO, and Siro + Nin groups,
respectively); 1-way ANOVA, Tukey’s multiple-comparisons test. (N) Scatter plots measuring AVM number, vein diameter, and vascular plexus density in
the retina of P9 pups treated as in Figure 2A. Data represent individual retinas and mean ± SEM (n = 7, 7, and 8 mice for the CTRL, DMSO, and Siro + Nin
groups, respectively); AVM number and vein diameter analyses: 1-way ANOVA, Tukey’s multiple-comparisons test; vascular density analysis: KruskalWallis test, post hoc Dunn’s multiple-comparisons test. **P < 0.01; ****P < 0.0001.

the decrease in hematocrit level, RBC number, and hemoglobin
level (Figure 2B), as well as blocked cardiomegaly, splenomegaly, and the loss of splenic architecture (Figure 2, C and D). Thus,
Siro + Nin combination treatment prevented anemia and retinal
bleeding in tBMP9/10ib mice.
946
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Because evidence is mounting that AVM development is controlled by blood flow (43) and because P9 tBMP9/10ib mice display significant cardiomegaly, we asked (a) whether tBMP9/10ib
mice develop cardiac defects leading to higher cardiac output and
(b) whether the drugs could indirectly reduce vascular pathology

The Journal of Clinical Investigation  

Figure 4. Siro + Nin reverses retinal vascular pathology in tBMP9/10ib
mice. (A) Schematic representation of the protocol for disease induction
and drug treatments. Pups were euthanized at P9. (B and C) Scatter plots
measuring AVM number, vein diameter, vascular plexus density (B), and
AVM diameter (C) in the retina of CTRL and tBMP9/10ib mice treated as in
A. Data represent individual retinas and mean ± SEM (n = 9, 8, and 7 mice
for the CTRL, DMSO, and Siro + Nin groups, respectively); AVM number and
vascular density analyses: 1-way ANOVA, Tukey’s multiple-comparisons
test; AVM diameter analysis: Mann-Whitney test; vein diameter analysis:
Kruskal-Wallis test, post hoc Dunn’s multiple-comparisons test; **P <
0.01; ***P < 0.001; ****P < 0.0001.

by correcting these cardiac defects. Although a modest decrease
in heart rate was measured by Doppler ultrasonography upon
drug treatment in tBMP9/10ib mice, heart rate was overall not
significantly changed in DMSO-treated and Siro + Nin–treated
tBMP9/10ib pups compared with normal pups (Supplemental
Figure 3A). In addition, no significant defects in cardiac output
(Supplemental Figure 3B) or pulmonary arterial pressure (Supplemental Figure 3C) measures were found between all groups.
These data demonstrate that basic cardiac function is normal in
tBMP9/10ib pups, at least until P9, and that Siro + Nin combination treatment is therefore unlikely to act on the vasculature by
changing cardiac output.
Siro + Nin reverses vascular pathology in tBMP9/10ib mice. We
next analyzed the retinal vasculature of P9 tBMP9/10ib mice
treated or not with Siro + Nin. On average, approximately 4 AVMs
were detected in tBMP9/10ib mice (Figure 3N and Supplemental
Figure 4), indicating that no additional AVMs developed between
P6 (mean = 3.79 ± 0.30, Figure 1Q) and P9. Strikingly, Siro + Nin–
treated P6 mice still contained some AVMs (n = 0.35 ± 0.11, Figure 1Q), but the P9 tBMP9/10ib mouse retinas that were treated
with the drugs for 3 additional days were devoid of AVMs (Figure

RESEARCH ARTICLE

3N and Supplemental Figure 4). In addition, the 6-day Siro + Nin
treatment (P3–P8, Figure 2A), as we observed after the 3-day Siro
+ Nin treatment (P3–P5, Figure 1), fully prevented vein dilation
and hypervascularization (Figure 3N and Supplemental Figure 4).
LC-MS analyses measured an increase in average drug concentrations in the pup serum between P6 and P9: from 9.0 nM to 22.6
nM Siro and from 5.3 nM to 24.7 nM Nin, indicating that 3 additional days of drug treatment led to an accumulation of the drugs
in the circulation.
These data suggest that Siro + Nin treatment might also
reverse existing AVMs, since some AVMs disappeared between P6
and P9. To directly address this possibility, we implemented a protocol that started the drug treatment after retinal vascular pathology was established. Specifically, pathology was induced as before
at P3 and pups were then treated at P6 with Siro + Nin, a time point
where we have established the presence of robust vein dilation,
hypervascularization, and of approximately 4 AVMs per retina
(Figure 1). Pups were treated for 3 days, from P6 to P8 (P6–P8),
and analyzed at P9 (Figure 4A). We found that Siro + Nin administered after pathology induction significantly reduced overall vascular pathology (Supplemental Figure 5), including AVM number,
AVM size, vein dilation, and vascular density (Figure 4, B and C).
In addition, P6–P8 Siro + Nin treatment significantly increased
hematocrit level, RBC number, and hemoglobin level in anemic
tBMP9/10ib mice (Figure 2B).
Because disease induction was triggered by only 1 i.p. injection at P3 of anti-BMP9/10 antibodies, we verified that the
observed effects of Siro + Nin in P9 pups were not facilitated by
a disappearance of the disease-causing anti-BMP9/10–blocking
antibodies from the pup circulation. Using specific anti-BMP9
and anti-BMP10 antibody ELISAs, we found that serum antibody concentrations were stable between P6 and P9, and reached
approximately 70 μg/mL for the anti-BMP9 antibody and approximately 85 μg/mL for the anti-BMP10 antibody (Supplemental
Figure 6). Thus, the disease-causing effects of the anti-BMP9/10
antibodies were maintained between P6 and P9, and therefore,
the drug combination effect on preexisting AVMs occurred in a
maintained pathogenic environment. Taken together, these findings demonstrate that Siro + Nin combination treatment not only
prevented, but also reversed, the retinal vascular pathology of the
tBMP9/10ib mice.
Siro + Nin prevents vascular pathology in the oral mucosa and
lungs of the tBMP9/10ib mice. The oral mucosa and lungs are
major sites of vascular lesion development in patients with HHT.
We investigated whether vascular defects were observed in these
tissues of the P9 tBMP9/10ib mice. Injections of latex blue dye
in the blood circulation were used to visualize vascular pathology. In the tBMP9/10ib mouse tongue and palate, mucosal vein
dilation and hyperproliferative vascular defects were clearly
identified after latex dye injection (Figure 5, A, B, D, and E). Significant enlargements of the lingual and greater palatine vessels
could be measured compared with control tongues and palates
(Figure 5J). In the lungs, the dye invaded a hypervascularized
network of dilated small vessels throughout the lobar system and
revealed an enlargement of the main pulmonary vessels of the
tBMP9/10ib mice (Figure 5, G, H, and J). Siro + Nin treatment of
the tBMP9/10ib mice significantly and efficiently prevented the
jci.org   Volume 130   Number 2   February 2020
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Figure 5. Siro + Nin prevents vascular
pathology in the oral mucosa and lungs
of the tBMP9/10ib mice. (A–I) Representative images of latex blue dye–perfused
mouse tongue, palate, and lungs of control
(CTRL; A, D, and G) and tBMP9/10ib mice
treated with DMSO (B, E, and H) or Siro
+ Nin (C, F, and I), as in Figure 2A. Yellow
arrowheads indicate lingual, palatine,
and pulmonary vessels used for diameter
measurements; black arrow denotes a
dilation of a lateral branch in the palatine
vasculature (E). Scale bars: 500 μm (A–F)
and 2 mm (G–I). (J) Scatter plots measuring
lingual, palatine, and pulmonary vessel
diameter. Data represent mean ± SEM; lingual vessel diameter analysis (n = 3, 4, and
3 mice for the CTRL, DMSO, and Siro + Nin
groups, respectively): Kruskal-Wallis test,
post hoc Dunn’s multiple-comparisons
test; palatine (n = 2, 3, and 4 mice) and
pulmonary (n = 10, 6, and 6 mice) vessel
diameter analyses: 1-way ANOVA, Tukey’s
multiple-comparisons test. **P < 0.01;
***P < 0.001; ****P < 0.0001.

hyperproliferative vascular pathology and vessel dilation phenotype observed in the tongue, palate mucosa, and lungs (Figure 5).
Thus, Siro + Nin combination treatment reduced vascular pathology in the oral mucosa and lungs.
Siro + Nin treatment corrects a gene expression signature and prevents vascular pathology in the liver of the tBMP9/10ib mice. The liver
is the most vascularized organ of the body and is a major site of vascular lesion development in patients with HHT, more specifically
HHT2 (44). We next investigated whether vascular defects could
be observed in the livers of the P9 tBMP9/10ib mice. Vascular
pathology induction and drug treatments in pups were performed
as above (Figure 2A). Latex dye tissue invasion was enhanced in
the tBMP9/10ib mouse livers and revealed a significant enlargement of the hepatic vessels (Figure 6, A, B, and D). H&E staining
showed the presence of marked local liver injury, characterized by
the presence of significant hepatocyte vacuolation and hepatocellular necrosis (Figure 6, E, F, H, and I, and Supplemental Figure 7),
a pathology that could result from ischemic events.
To gain insight into the mechanism of liver injury, we performed a proteome array for angiogenesis-related factors. This
948

jci.org   Volume 130   Number 2   February 2020

screen identified plasminogen activator inhibitor 1 (PAI-1) as a
protein strongly upregulated in the tBMP9/10ib mouse livers compared with livers from control mice (Figure 6K). PAI-1 is of interest
because it is upregulated during hypoxia (45), and might thus represent a response to ischemia. PAI-1 elevation in the tBMP9/10ib
mouse livers was confirmed by Western blot (Figure 6L) and IHC
(Figure 6, M, N, and P) analyses. To verify that hypoxia was occurring in the tBMP9/10ib mouse livers, tissue sections were stained
for hypoxia-inducible factor 1α (HIF-1α), a transcriptional factor
marker and master regulator of hypoxia (46). We found a strong
upregulation of liver HIF-1α expression in tBMP9/10ib mice compared with control mice (Figure 6, Q, R, and T). These data show
that tBMP9/10ib mice develop a robust vascular pathology in the
liver. Strikingly, Siro + Nin treatment of the tBMP9/10ib mice significantly prevented the hyperproliferative vascular pathology and
vessel dilation phenotype of the liver (Figure 6, A–D). In addition,
Siro + Nin efficiently reduced hepatocyte vacuolation and necrosis
(Figure 6, E–J, and Supplemental Figure 7), as well as prevented the
overexpression of PAI-1 and HIF-1α in the liver of the tBMP9/10ib
mice (Figure 6, M–T). Together, these results demonstrate that
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Figure 6. Liver vascular pathology and liver disease in tBMP9/10ib mice: Effects of Siro + Nin treatment. (A–C) Latex blue dye–perfused livers from
tBMP9/10ib mice treated with vehicle (DMSO; B) or Siro + Nin (C), and control mice treated with DMSO (CTRL; A), as in Figure 2A. (D) Scatter plot measuring hepatic vessel diameter. Diameters of these vessels (most likely arterial) were measured at 2,000 μm (orange dotted lines) from the margin of the
liver (gray dotted lines). Data represent mean ± SEM (n = 4 livers per condition); Kruskal-Wallis test, post hoc Dunn’s multiple-comparisons test. (E–J) Liver
sections stained with H&E at low magnification (E–G) and high magnification (H–J) from tBMP9/10ib and CTRL mice treated as in A–C; insets in H–J indicate magnified areas. (K–O) PAI-1 immunodetection by proteomic array (K, pooled homogenates from n = 3 mice) and Western blot (L, n = 3 mice) of liver
homogenates, and by immunofluorescence staining in liver sections (M–O) from mice treated as in A–C. (P) Scatter plot measuring PAI-1 levels, expressed
as a mean intensity of fluorescence per sampled area. Data represent mean ± SEM (n = 3 livers per condition); Kruskal-Wallis test, post hoc Dunn’s multiple-comparisons test. (Q–S) HIF-1α IHC in liver sections from mice treated as in A–C; insets indicate magnified areas. Histology data are representative of
at least 3 independent mice/condition. Scale bars: 1000 μm (A–C), 3 mm (E–G), 100 μm (H–J, M–O, and Q–S), 35 μm in insets (H–J and Q–S). (T) Scatter plot
measuring HIF-1α levels, expressed as a mean intensity of fluorescence per sampled area. Data represent mean ± SEM (n = 3 livers per condition); 1-way
ANOVA test, post hoc Tukey’s multiple-comparisons test. *P < 0.05; **P < 0.01; ****P < 0.0001.

Siro + Nin combination treatment prevented vascular pathology in
the liver and blocked liver disease in tBMP9/10ib mice.
To further test the therapeutic potential of the Siro + Nin combination, we determined (a) whether gene expression changes

could be detected in the tBMP9/10ib whole-liver tissue and (b)
whether treatments with the 2 drugs (administered alone or in
combination) could correct these transcriptomic changes. When
we plotted the transcript expression changes (measured as log fold
jci.org   Volume 130   Number 2   February 2020
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Figure 7. Siro + Nin corrects a gene expression signature detected in
the tBMP9/10ib mouse liver. (A) Scatter plots comparing the liver gene
expression changes (logFC, log fold change) observed upon treatment
with Siro + Nin or individual drug (Siro or Nin), to the liver gene expression
logFCs observed between tBMP9/10ib and normal control (CTRL) mice.
Treatments were as in Figure 2A. The negative slope of the plots indicates
that each treatment contributed to normalizing the liver gene expression
changes seen in tBMP9/10ib versus CTRL mice. Correlation coefficients (r2)
indicate a more robust normalization with the drug combination than with
individual drugs. (B) Heatmap of liver transcripts synergistically differentially expressed by the drug combination. We identified the genes that
responded to the drug combination differently than would be expected,
assuming an additive effect of both drugs. A noninteracting drug would
produce a COMBO expression equal to the average of the gene expression
measured with each treatment (NIN or SIRO). The significant effects
that we detected, measured with the statistical contrast COMBO – (NIN
+ SIRO)/2, produced gene expression changes that deviate from this
average independent effect expectation. Transcripts were selected with
FDR ≤ 0.5%, log average expression > –5. For reference, liver transcripts in
CTRL mice are shown on the heatmap. Gene expression in CTRL mice was
used for normalization, but was not used in the selected transcripts that
displayed synergistic drug response.

change values, logFC) in tBMP9/10ib pups versus normal controls, against the transcript expression logFCs obtained after treating the tBMP9/10ib pups with Siro + Nin versus vehicle (DMSO),
an inverse correlation was found for Siro + Nin treatment (r2 =
0.380, P < 0.001; Figure 7A). An inverse correlation indicates that
Siro + Nin treatment normalized some of the changes observed
in the disease model (tBMP9/10ib pups) compared with normal
controls. When the same comparison was done for Siro and Nin
administered alone, a weaker correlation was measured (r2 = 0.193
and 0.190, respectively, P < 0.001; Figure 7A). These results indicate that Siro + Nin combination better corrected the expression
changes of liver transcripts detected in the tBMP9/10ib mice than
either drug administered alone.
To illustrate the synergistic effect of Siro and Nin treatments
on transcript expression, we identified transcripts that were differentially changed by the drug treatments in the tBMP9/10ib liver (n
= 6–9 biological replicates/group, FDR ≤ 0.5%, log average expression > –5; Figure 7B, Supplemental Figure 8 and Supplemental
Table 1). The black box in the heatmap of Figure 7B shows a subset
of transcripts that were (a) significantly changed by Siro + Nin; (b)
not changed by either Nin or Siro administered in isolation; and (c)
whose expression was normalized, as compared with normal controls. This subset of transcripts confirms that a synergistic effect
exists between Siro and Nin treatments at the gene expression
level, and that this effect could normalize a subset of deregulated
transcripts in the tBMP9/10ib liver. A functional enrichment analysis of the identified subset of normalized transcripts did not identify genes already reported to be involved in HHT or AVMs, but
identified instead a network of genes involved in cell and protein
metabolism (e.g., Uba6, Tmem56, mt-Nd3, Kdm1b, Gclc, Prkd3;
GeneMANIA, ref. 47), a response indicative of strong and predominant gene expression changes consecutive to liver injury and
deregulations in cell homeostasis.
Together, these transcriptomic data show that Siro and Nin
treatments synergized and partially opposed a deregulated gene
expression signature detected in the tBMP9/10ib liver. These
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results are important because they confirm the interaction and
combination efficacy of the 2 drugs in reducing overall vascular
pathology in tBMP9/10ib mice.
Siro + Nin reduces GI bleeding and anemia in adult Alk1-iKO
mice. The effect of the drug combination was evaluated in an adult
Alk1 inducible knockout (iKO) mouse model (R26CreER/+ Alk12f/2f).
In this model, ALK1 deficiency was induced by tamoxifen administration to generate severe GI bleeding and anemia in 9 days
(Figure 8 and refs. 39, 48). Daily treatment with the same doses of
Siro + Nin used for the tBMP9/10ib mice (0.5 mg/kg Siro and 0.3
mg/kg Nin, i.p.), starting at the time of tamoxifen injection, significantly reduced GI bleeding (Figure 8, A–D) and partially, but
significantly, increased hematocrit level, RBC number, and hemoglobin level (Figure 8, E–G) compared with the vehicle-treated
Alk1-iKO controls.
In tBMP9/10ib mice, Siro prevents mTOR overactivation, and Nin
blocks overactivated VEGFR2. We next assessed mTOR signaling
in tBMP9/10ib mice by measuring the levels of phospho-mTOR
(p-mTOR) and phospho-S6 (p-S6) in the liver and retina. Western
blot analyses revealed robust increases in p-mTOR and p-S6 levels
in whole-liver homogenates isolated from tBMP9/10ib mice compared with control mice (Figure 9A). Treatment with Siro (alone
or in combination with Nin) blocked S6 phosphorylation and normalized p-mTOR levels in the tBMP9/10ib mouse liver (Figure
9A and Supplemental Figure 9). Examination of the tBMP9/10ib
retinal tissue confirmed the presence of strong p-S6 immunoreactivity in the AVMs, which could significantly be blocked by Siro
treatment of the mice (Figure 9, B and C).
A significant elevation of activated phospho-VEGFR2
(p-VEGFR2) was detected in protein homogenates of liver ECs
isolated from tBMP9/10ib mice (Figure 9D and Supplemental Figure 10) and in the tBMP9/10ib mouse retina (Figure 9E), which
was significantly inhibited by Nin treatment of the mice (Figure 9,
D–F, and Supplemental Figure 11). We also verified that the drug
combination did not interfere with the inhibitory effect of Nin on
p-VEGFR2. As observed upon treatment with Nin alone, Siro +
Nin fully inhibited VEGF-induced VEGFR2 activation in primary
ECs (Supplemental Figure 2). Altogether, these data confirmed
that endothelial mTOR and VEGFR2 were overactivated in the
tBMP9/10ib mice and that Siro + Nin could respectively and efficiently block these signaling deregulations in vivo.
Siro rescues Smad1/5/8 signaling by activating ALK2. Because
the possibility that Siro might both prevent mTOR overactivation
and rescue Smad1/5/8 signaling in HHT mice is appealing, we
revisited the effect of Siro on Smad1/5/8 signaling in cell culture
systems. We found that Siro increased Smad1/5/8 phosphorylation (p-Smad1/5/8) in a dose-dependent manner and increased
the levels of the Smad1/5/8 downstream target ID1 (inhibitor of
differentiation 1) in C2C12 myoblast cells (Supplemental Figure
12A) and in human umbilical vein ECs (HUVECs, Figure 10A), at
doses very comparable to Tac (32). A pharmacological approach
using the pan-ALK inhibitor LDN-193189 (Figure 10B) and gene
silencing (Figure 10C and Supplemental Figure 12B) in HUVECs
further showed that ALK2 is required for the stimulatory effect of
Siro on Smad1/5/8 signaling.
To further demonstrate efficacy in a cell culture system more
directly relevant to the pathophysiology of human HHT, we used
jci.org   Volume 130   Number 2   February 2020
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Discussion

Major progress in techniques of interventional radiology, embolization, and cauterization have considerably reduced the risk of hemorrhage in patients
with HHT. However, the recurring and progressive
nature of the disease continues to make HHT a highly
debilitating disorder associated with life-threatening
sequelae. Several disease-modifying therapies have
been proposed in preclinical models, and some of
them are currently being investigated in clinical trials (49). Notably, Tac was found to be associated with
Smad1/5/8-activating properties in ECs and showed
some efficacy in reducing pathology in HHT (32) and
PAH (37) models and patients (50–52). Here we propose that Siro, a structural analog of Tac and inhibitor
of mTOR, is a more potent blocker of AVM development in HHT mice. We found that Siro acts as a dual
modulator by stimulating Smad1/5/8 while inhibiting
mTOR, in cell cultures and HHT mice, thus correcting 2 key signaling defects of the HHT ECs.
In cell cultures, Tac was proposed to activate
Smad1/5 by facilitating dissociation of the binding repressor FKBP12 from ALK1, ALK2, and ALK3,
while Siro only recruited ALK2 (37). Here, we confirmed in HUVECs that Siro could activate endothelial Smad1/5/8 by specifically stimulating ALK2.
Although these data would need to be confirmed in
vivo, they suggest the intriguing possibility that ALK2
activation might compensate for ALK1 loss of function. Although attractive from a mechanistic aspect,
this mechanism might be risky because ALK2activating mutations are associated with fibrodysplasia ossificans progressiva, a disorder characterized
by progressive heterotopic bone formation in muscle
tissues (53). However, both Tac and Siro are not
known to lead to any adverse effects associated with
mechanisms of abnormal ossification in humans. In
Figure 8. Siro + Nin effectively reduces GI bleeding and ameliorates anemia in adult
addition, Siro showed a potent anti-AVM effect at
Alk1-iKO mice. (A–C) GI tract from stomach to rectum of 2- to 4-month-old CreER-negadoses (9–22 nM in mouse serum) comparable to its
tive control (CTRL; A) and Alk1-iKO mice treated with vehicle (DMSO; B) or Siro + Nin (C).
Higher magnifications show the cecum. Scale bars: 10 mm (A–C). (D–G) Scatter plots meause in the clinical setting (whole-blood trough consuring cecum bleeding index (D), hematocrit (HCT) level (E), red blood cell (RBC) number
centrations of ~15–20 nM for prophylaxis of trans(F), and hemoglobin (Hb) level (G). Data represent mean ± SEM (n = 2–4, 7–8, and 10 mice
plant rejection, for instance).
for the CTRL, DMSO, and Siro + Nin groups, respectively); 1-way ANOVA (D–F) and 2-way
Our data highlight a beneficial interaction and
ANOVA (G), Tukey’s multiple-comparisons test. **P < 0.01; ***P < 0.001; ****P < 0.0001.
synergy between Siro and Nin treatments in HHT
CBC parameters of the controls were within the expected ranges for adult mice.
mice. This interaction was observed by RNA sequencing (RNA-Seq) of the tBMP9/10ib liver, which revealed
blood outgrowth ECs (BOECs) isolated from a patient with HHT2
the presence of deregulated genes that were fully normalized only
genetically confirmed to carry the disease-causing ALK1 T372fsX
when Siro and Nin were coadministered. This transcriptional intertruncation (32). Treating these HHT2 patient BOECs with Siro
action translated into a robust synergy of the 2 drug treatments and
also increased p-Smad1/5/8 and ID1 levels (Figure 10D). Finally,
a significant improvement of the Siro effect at preventing AVMs in
IHC analyses showed that in vivo Siro was able to modestly but
HHT mice. We found that Nin acted, at least in part, by blocking
significantly rescue the decrease in p-Smad1/5/8 in the retinal
the overactivation of VEGFR2 in ECs of the tBMP9/10ib mice. Nin
vasculature (Figure 11, A and B, and Supplemental Figure 13).
is not specific to VEGFRs, as it also targets FGFRs and PDGFRs,
Thus, Siro displayed potent in vitro Smad1/5/8 signaling activat2 other receptor families involved in angiogenesis (54). Further
ing properties in EC cultures, including in HHT patient–derived
investigation will be needed to determine whether interference of
ECs, and significantly rescued Smad1/5/8 loss of function in vivo
these other RTK receptor pathways might be involved in the antiin tBMP9/10ib mice.
AVM effect of the Siro + Nin combination. Previous work suggests,
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Figure 9. Siro prevents mTOR
overactivation, and Nin blocks
overactivated VEGFR2 in
tBMP9/10ib mice. (A–F) Control
(CTRL) and tBMP9/10ib mice
were treated with DMSO and
Siro (A–C) or Nin (D–F). Protein
homogenates of whole liver
from P6 mice (A) and of liver ECs
isolated from P9 mice (D) were
analyzed by Western blot using
antibodies directed against the
indicated proteins. Scatter plots
show areas positive for p-S6
(B) and p-VEGFR2 (E) analyzed
by IHC in the retina of P6 CTRL
and tBMP9/10ib mice treated
with DMSO and Siro (B) or Nin
(E), expressed as a percentage
of the retinal vascular area
occupied by immunofluorescence
staining. Data represent mean
± SEM (n = 4, 3, and 3 mice for
the CTRL, DMSO, and Siro [B]
or Nin [E] groups, respectively);
p-S6 analysis: Kruskal-Wallis
test, post hoc Dunn’s multiple-comparisons test; p-VEGFR2
analysis: 1-way ANOVA, Tukey’s
multiple-comparisons test. ***P
< 0.001; ****P < 0.0001. Representative immunofluorescence
images show P6 retinas from
tBMP9/10ib mice treated as in B
and E stained with fluorescent
isolectin B4 (green, C and F),
anti-p-S6 (magenta, C), anti–pVEGFR2 (red, F), and anti-Erg
(white, F) antibodies. Scale bars:
100 μm (C) and 50 μm (F).
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Figure 10. Siro activates Smad1/5/8 via ALK2. (A–D) HUVECs (A–C) and HHT2 patient–derived BOECs (D) were treated for 3 hours with vehicle (DMSO) or Siro
in complete medium (conditioned for 2–3 days) and at the indicated concentrations (A and D) or at 300 nM (B and C), in the absence or presence of LDN-193189
(LDN, 1 μM, B), or the indicated siRNA treatments (C). Cell extracts were analyzed by Western blot using antibodies directed against the indicated proteins.

however, that this might not be the case for PDGFRs, since PDGF
signaling activation (not inhibition) was found to mitigate vessel
wall defects in an Eng-KO mouse model (55).
The current data provide further evidence that HHT pathogenesis requires the overactivation of the mTOR and VEGFR2
pathways (Figure 11C). How Smad1/5/8, mTOR, and VEGFR2
control each other during the disease process remains unclear.
Although loss-of-function mutations in BMP9/ALK1/endoglin/
Smad4 signaling are necessary to cause HHT, they are not sufficient. Indeed, additional genetic, environmental, and/or developmental modifiers are required for AVM development, a process
referred to as the double/multiple hit hypothesis (56). Notably,
VEGF stimulation or wounding, 2 triggers of angiogenesis, were
reported to be required to generate brain and skin AVMs in adult
ALK1-deficient mice (43). Furthermore, in HHT neonate mouse
models, including in tBMP9/10ib pups, it is believed that retinal
AVMs develop spontaneously and aggressively because vessel
development is actively occurring through angiogenesis. Synergy
between BMP9/10 blocking and VEGFR2 activation during the
normal process of angiogenic vascular development would thus
provide in these models the ideal milieu for lesion development.
Therefore, although there is now strong evidence that Smad1/5/8
reduction overactivates VEGF signaling to cause vascular pathology, these 2 pathways are initiated by independent triggers. Our
data showing that Nin and Siro treatments have clear synergistic
effects support this notion and further show that the 2 pathways
can independently signal in ECs to cause AVMs.
Recent studies have demonstrated that PI3K/Akt signaling is overactivated in several HHT models, and that its inhibition reduces the AVMs (25, 30, 31). In line with this observation,
we show here that, in the tBMP9/10ib mouse liver, there is an
increase in p-Ser2448-mTOR, a phosphorylation mostly associated
with mTORC1, the mTOR complex downstream from PI3K/
Akt, which is directly targeted by Siro (57). In addition, Siro treatment, which fully prevented p-Ser2448-mTOR and S6 overactivation, reduced AVM number in our model, suggesting that mTOR,
most likely downstream from PI3K/Akt, is a major player in AVM
development. We further found that, although Siro fully inhibited
mTOR overactivation in vivo, its anti-AVM effect was only partial
and could be significantly potentiated upon VEGFR2 inhibition
by Nin, indicating that VEGFR2 can signal independently of the
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PI3K/Akt/mTOR pathway to control the AVMs. This observation
concurs with recent data obtained in Smad4-deficient mice, which
indicate that abnormal PI3K/Akt activation in ECs is primarily
controlled by blood flow and not VEGFR2 (24, 58).
An important question relates to the drug dosing used in this
study and whether it allows the administered drugs to reach concentrations within the expected therapeutic range. We measured
an average of 9.0 nM Siro and 5.3 nM Nin at P6, and an increase to
22.6 nM Siro and 24.7 nM Nin at P9 in the pup serum. Previously
published in vitro experiments reported a Siro IC50 of approximately 0.1 nM for mTOR (59) and a Nin IC50 of approximately 13
nM for VEGFR2 (60). At the tested dosing, circulating concentrations of Siro and Nin are therefore expected to inhibit in vivo
mTOR and VEGFR2, which is in line with the observed effects
on these targets in tBMP9/10ib mice (Figure 9). For Smad1/5/8
stimulation by Siro, our experiments in HUVECs showed that
the lowest effective concentration is 100 nM (Figure 10A), which
is about 4 times higher than the concentration detected in the
serum. We found nonetheless that Siro treatment modestly but
significantly increased p-Smad1/5/8 in the mouse retina, indicating that the drug was delivered in sufficient quantities to
stimulate Smad1/5/8 signaling in vivo (Figure 11). We have not
obtained clear experimental data that explain this apparent discrepancy. However, it is important to note that concentrations
used in vitro and drug serum concentrations are difficult to compare. Indeed, drug concentration measurements in the circulation do not consider the pharmacokinetics and bioavailability of
the drugs. One important parameter is cellular uptake and accumulation, which can significantly reduce serum concentration
while increasing local drug delivery. Altogether, these data suggest that the administered drugs reached concentrations within
the expected therapeutic range.
We found that Siro + Nin treatment prevented anemia in P9
tBMP9/10ib pups and significantly improved the CBC parameters in adult Alk1-iKO mice (Figure 2B and Figure 8, D–G). In
tBMP9/10ib pups, drug treatment generated a supranormal elevation of the CBC parameters. In some models of anemia, Siro
was reported to ameliorate anemia by increasing stress erythropoiesis (61). In this context, the supranormal elevation of the CBC
parameters measured after drug treatment could be due, in part,
to changes in erythropoiesis. To test this hypothesis, additional

The Journal of Clinical Investigation  

RESEARCH ARTICLE

Figure 11. Siro rescues Smad1/5/8
signaling in the tBMP9/10ib retina. (A)
Scatter plot measuring p-Smad1/5/8–
positive area in the retina of P6 control
(CTRL) and tBMP9/10ib mice treated with
DMSO or Siro, expressed as a percentage
of the retinal vascular area occupied by
immunostaining. Data represent mean
± SEM (n = 4, 3, and 3 mice for the CTRL,
DMSO, and Siro groups, respectively).
***P < 0.001, ****P < 0.0001; 1-way
ANOVA, Tukey’s multiple-comparisons
test. (B) Representative images showing
P6 retinas from tBMP9/10ib mice treated
as in A stained with fluorescent isolectin
B4 (green), anti-Erg (white), and anti–
p-Smad1/5/8 (red). Scale bars: 50 μm. (C)
Schematic illustration of the proposed
synergistic effects of Siro and Nin on
endothelial Smad1/5/8, mTOR, and
VEGFR2 signaling pathways.

experiments were performed by using the recently described
method of monitoring erythropoiesis using CD44/Ter119/FSC as
markers of terminal erythroid differentiation (62). We measured
a significant increase in the number of reticulocytes in the bone
marrow, but not in the spleen, of Siro + Nin–treated tBMP9/10ib
mice (Supplemental Figure 14). These data suggest that although
no stress erythropoiesis was observed, an increase in RBC production occurred and thus could explain, at least partly, the supranormal levels of hematocrit, RBCs, and hemoglobin measured
after the drug treatment. Further investigation will be required to
clearly define the origin of the observed effects, for instance, by
looking at the earlier RBC precursors (62). Other experiments will
also be needed to precisely determine how much of the corrected
anemia is driven by a bleeding reduction (Figure 3M) versus an
increased RBC production (Supplemental Figure 14) and whether
the drug effect on RBC production could be related to developmental aspects in newborn mice. In support of the latter possibility, a supranormal elevation of the RBC counts was not found
in treated adult Alk1-iKO mice (Figure 8), further supporting our
current interpretation that anemia correction is primarily driven
by a bleeding reduction.

Prophylaxis of rejection in liver transplantation includes
treatment with immunosuppressive drugs, primarily Tac and
more rarely Siro. Recently, liver AVM pathology recurrence was
reported in patients with HHT who underwent liver transplantation while they were treated with Tac (63). Our study suggests the
possibility that prioritizing Siro versus Tac (together or not with
Nin) in the antirejection regimen might also help in specifically
preventing the spread of vascular disease in healthy liver grafts.
More broadly, the beneficial effect of Siro and mTOR inhibition has already been described in models of pathological angiogenesis (64). In addition, Siro treatment has produced promising results in patients affected by vascular anomalies (65). Our
observation that Siro and Nin mechanistically synergize to block
the pathogenic process of HHT might thus have important ramifications for the treatment of other vascular disorders, such as the
vascular anomaly diseases.
In conclusion, the present data show that Siro + Nin combination treatment concurrently normalizes endothelial Smad1/5/8,
mTOR, and VEGFR2 pathways to synergistically and efficiently
oppose HHT pathogenesis and the associated vascular pathology in neonate and adult mouse models of the disease. We
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thus propose that Siro + Nin combination treatment has thera
peutic potential in HHT.

Methods

Mice. This study was performed using C57BL/6J mice (The Jackson
Laboratory). R26-CreER/+ Alk12f/2f mouse generation and Alk1 deletion
using tamoxifen were described previously (39, 48). Mice were maintained in regular housing conditions and were allowed free access to
water and a maintenance diet.
Transmammary-delivered immunoblocking of BMP9 and BMP10
and drug treatments. tBMP9/10ib pups and age-matched control
pups (treated with isotype controls) were generated as previously described (22, 32). Pups (litter size, n = 7–9 mice; average mouse
weight, 2 g) were treated with vehicle (0.1% DMSO in saline), Siro
(0.5 mg/kg BW), and Nin (0.3 mg/kg BW) following the different
combinations and schedules described in the figures. Isotype control
pups were injected with vehicle.
RNA-Seq, read alignments, and gene expression differential expression
analysis. RNA was processed for RNA-Seq at the Genomics Resources
Core Facility, Weill Cornell Medical College, on an Illumina
HiSeq 4000 instrument. Alignments of reads to the transcriptome were performed with Kallisto version 0.44.0. We aligned
reads to the mouse transcriptome downloaded from Ensembl
(Mus_musculus.GRCm38.cdna.all.fa.gz). Alignment was run on
a MacOS laptop with 16 GB of memory, using the NextflowWorkbench (66) to orchestrate alignment and count aggregation for the
analyzed samples. RNA-Seq transcript counts were analyzed with
analysis scripts written with the MetaR languages (67). Reads were
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